stockportfolio.pro
SI-BONE, Inc. (SIBN)
Healthcare · Medical Devices · NasdaqGM
SI-BONE, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.98M | $55.38M | $67.30M | $73.39M | $90.15M | $106.41M | $138.89M | $167.18M | $200.93M |
| Gross profit | $42.87M | $50.55M | $60.51M | $64.48M | $79.72M | $90.70M | $109.42M | $132.12M | $159.88M |
| Net income | $-23.04M | $-17.45M | $-38.40M | $-43.70M | $-56.57M | $-61.26M | $-43.34M | $-30.91M | $-18.90M |
| Net margin | -48.0% | -31.5% | -57.1% | -59.5% | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
Source: SI-BONE, Inc. SEC filings (10-K).
Explore 9 years of SI-BONE, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SIBN in your portfolio →
SI-BONE, Inc. financial history by metric
About SI-BONE, Inc.
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
SI-BONE, Inc. — frequently asked questions
What is SI-BONE, Inc.'s revenue?
SI-BONE, Inc. (SIBN) reported revenue of $200.93M for fiscal year 2025, up 20.2% from the prior year, according to its SEC filings.
Is SI-BONE, Inc. profitable?
No — SIBN reported a net loss of $-18.90M in fiscal 2025.
What is SIBN's P/E ratio?
SI-BONE, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is SI-BONE, Inc. growing?
SIBN's revenue grew at roughly 22.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does SI-BONE, Inc. have?
As of fiscal year 2025, SIBN carried roughly $35.57M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is SI-BONE, Inc.'s gross margin?
SIBN's gross margin was 79.6% in fiscal 2025 — gross profit of $159.88M on revenue of $200.93M.
What is SI-BONE, Inc.'s market cap?
SI-BONE, Inc. (SIBN) has a market capitalization of about $681.20M, based on the latest data in our nightly-refreshed cache.
When does SI-BONE, Inc.'s fiscal year end?
SIBN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from SI-BONE, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.